This is a direct award to the incumbent supplier Poundbury Cancer Institute, under the Provider Selection Regime (PSR) using Process C. The contract is for the provision of outsourced histopathology reporting. The contract term is from 01/08/2026 to 31/03/2027 (with a 3 month termination notice clause by either party). This is a variable contract with no guarantee of volume or value. The estimated value is £237,528 based on previous spend. An option to extend for a further 3 months has been included, if the incumbent supplier can demonstrate it still meets the required service level criteria and fulfils the guidelines associated with Process C. As shown in the disclosed criteria, the main criterion is Quality. "Quality and Innovation" is weighted at 50% as the key objective is maintaining a high-quality service. The other elements of quality-led criteria total a further 40% of the weighting. Value in terms of cost has been weighted 10%, because maintaining the quality of the service is the main objective of this award. The Trust has measured the incumbent supplier's current and likely future performance against the criteria and confirm their recommendation to make a direct award via Process C.